AbbVie looks financially healthy for investors because growth from Skyrizi and Rinvoq is replacing much of Humira’s decline, while margins remain high Cash and liquidity appear adequate, supported by Q1 2026 cash and cash equivalents of $982B The balance sheet still needs monitoring because debt refinancing and acquisition-related costs remain important Capital returns look supported, but capital efficiency is mixed due to heavy R&D, M&A, and impairment risk
Financial Health Snapshot
What do AbbVie’s latest financial health metrics show?
Strong. AbbVie’s biggest strength is its revenue and margin scale, while the main concern is Humira decline and acquisition-related charges.
Using the latest verified periods, full-year 2025 and Q1 2026, this snapshot combines growth, profitability, cash generation, balance-sheet capacity, and capital efficiency. The result is a strong but not risk-free picture, with scale and liquidity offset by product and integration pressure.
For more background on AbbVie’s business model and how it makes money, see AbbVie Inc. (ABBV): History, Ownership, Mission, How It Works & Makes Money; the first metric to analyze deeper is revenue growth because it frames the rest of the snapshot.
Revenue and earnings quality
Is AbbVie’s revenue growth turning into earnings?
Mixed. AbbVie’s revenue growth is strong, but GAAP earnings conversion is less clear because the newest growth from Skyrizi and Rinvoq is offset by Humira decline and by acquired IPR&D, milestones, and impairment charges.
AbbVie’s growth is improving in quantity and quality, but not evenly across the income statement. Investors compare revenue durability with operating income, net income, and EPS over the same annual periods because revenue can rise while acquisition accounting, noncash charges, or share-based effects still weaken per-share earnings. See also Mission Statement, Vision, & Core Values (2026) of AbbVie Inc. (ABBV).
| Measure | Latest Period | Previous Period | Quality Test | Investor Meaning |
|---|---|---|---|---|
| Revenue | $61.16B, up 8.61%, full-year 2025 | Full-year 2024 revenue was not supplied | Organic growth, led by newer products | The growth looks more repeatable because Skyrizi and Rinvoq are scaling while Humira declines |
| Operating Income | $ not supplied, Q1 2026 | $ not supplied, previous comparable period not supplied | Direction cannot be verified from the supplied data | Operating leverage cannot be confirmed from the provided figures alone |
| Net Income | $699.00M, Q1 2026 | $ not supplied, previous comparable period not supplied | Acquired IPR&D, milestones, and impairment charges affect comparability | Final earnings are harder to read than revenue growth |
| Diluted EPS | $0.39, Q1 2026 | $2.36, full-year 2025 GAAP diluted EPS | Share-count impact is not the main issue; accounting items are | Per-share earnings did not mirror the stronger top-line trend |
How durable is AbbVie’s revenue growth?
The strongest durability signal is recurring prescription demand for Skyrizi and Rinvoq. The biggest visibility limit is concentration risk, since Humira erosion, payer pressure, and product-mix dependence can still swing results.
- Demand Quality: Prescription revenue is recurring, but it still depends on physician demand, payer access, and therapeutic uptake.
- Pricing and Volume: The price-volume split was not supplied, so the visible driver is the shift in mix toward Skyrizi and Rinvoq.
- Diversification: AbbVie remains concentrated in immunology, with Skyrizi, Rinvoq, and Humira carrying much of the growth and risk.
That makes profitability and cash conversion the next test.
Profitability & Cash
Are AbbVie’s margins and cash flow strong?
AbbVie’s operating margin was 7191% in Q1 2026, but the negative cash-flow growth signals mean reported earnings were not fully mirrored by cash conversion. High operating profitability still looks supportive, yet operating cash flow and free cash flow did not clearly confirm it.
Gross margin, operating margin, and net margin measure different layers of profit, while net income, operating cash flow, capital expenditure, and free cash flow show how much profit becomes cash. AbbVie also had $247B of R&D, $358B of SG&A, $71700M of interest expense, and $34200M of income tax expense in Q1 2026. For broader investor context, Exploring AbbVie Inc. (ABBV) Investor Profile: Who's Buying and Why? can help frame the cash-quality discussion.
| Measure | Latest Period | Previous Period | Verified Driver | Investor Meaning |
|---|---|---|---|---|
| Gross Margin | Not provided for Q1 2026. | Not provided for a comparable prior period. | Q1 2026 supplied gross profit of $1078B and revenue of $1500B, but no verified gross-margin percentage was supplied. | Product economics cannot be compared cleanly from the supplied margin data. |
| Operating Margin | 7191% in Q1 2026 | Not provided for a comparable prior period. | Operating income of $473B versus the reported Q1 2026 margin shows strong operating profitability, with R&D and SG&A still the main cost items. | Scale appears to support operating efficiency, but the supplied data does not give a prior margin for trend comparison. |
| Net Margin | Not provided for Q1 2026. | Not provided for a comparable prior period. | Net income of $69900M was pressured below operating profit by interest expense of $71700M and income tax expense of $34200M. | Final profitability may differ from operating strength when financing, taxes, and acquisition-related items are heavy. |
| Operating Cash Flow | Not provided; Operating Cash Flow Growth: -2662% for 2026-03-31 | Not provided for a comparable prior period. | The supplied growth signal points to weaker cash conversion, likely affected by working-capital movement and non-cash items. | Accounting earnings do not appear to translate cleanly into operating cash in the supplied period. |
| Free Cash Flow | Not provided | Not provided | Free cash flow was not supplied, so the capital-expenditure burden cannot be quantified from the prompt. | Remaining cash for reinvestment and financing cannot be verified from the available data. |
What most affects AbbVie’s cash conversion?
The biggest verified pressure is weaker cash conversion, with Operating Cash Flow Growth at -2662% and Free Cash Flow Growth at -2710%. Heavy R&D, SG&A, and acquisition-related non-cash items can make cash generation uneven.
- Main Driver: Working-capital movement and non-cash acquisition items look temporary, while R&D intensity is more structural.
- Evidence Gap: The prompt does not provide absolute operating cash flow, free cash flow, or capex values.
- Metric to Monitor: Track operating cash flow margin and free cash flow growth next.
Liquidity Pressure
Does AbbVie have enough liquidity and balance-sheet capacity?
Mixed. AbbVie has solid cash generation and access to financing, but leverage is still high and the main concern is refinancing and interest burden, especially with heavy acquisition-linked intangibles on the balance sheet. For mission context, see Mission Statement, Vision, & Core Values (2026) of AbbVie Inc. (ABBV).
Cash matters, but it is only one part of the picture. AbbVie’s balance-sheet strength depends on working capital, asset quality, debt service, solvency, liquidity, and refinancing access together, because a company can hold cash and still face pressure if current liabilities, debt, or intangibles become harder to manage.
| Area | Latest Evidence | Assessment | Investor Meaning |
|---|---|---|---|
| Cash and Working Capital | Q1 2026 cash and cash equivalents of $982B; FMP 2026-03-31 Cash And Cash Equivalents: $939B; Total Current Assets $3353B; Total Current Liabilities $4210B. | Mixed | Near-term obligations look tight because current liabilities exceed current assets, so cash helps but does not fully cover working-capital pressure. |
| Total and Net Debt | Total Debt $7286B; Net Debt $6347B; Short Term Debt $833B; Long Term Debt $6453B. | Mixed | Leverage is meaningful, so balance-sheet flexibility is not unlimited even with a sizable cash position. |
| Debt Service and Refinancing | February 26, 2026 $800B senior notes filing for general corporate purposes and debt refinancing. | Mixed | AbbVie appears to have refinancing access, but debt service and funding costs need close monitoring. |
| Asset Quality | Goodwill And Intangible Assets $8644B; Total Assets $13646B. | Weak | Acquisition-linked intangibles are a major exposure if earnings weaken or asset values are questioned. |
| Liabilities and Equity | Total Liabilities $10896B; Total Stockholders Equity $2750B. | Mixed | The equity base is positive, but liabilities remain large, so loss-absorption capacity is not especially strong. |
Which balance-sheet risk matters most for AbbVie?
Debt refinancing risk matters most. AbbVie’s $7286B of total debt, $6347B of net debt, and $800B senior notes filing make access to capital and interest burden the clearest pressure points.
- Current Exposure: Total Current Liabilities $4210B exceed Total Current Assets $3353B.
- Protection: Cash and cash equivalents of $982B in Q1 2026, or $939B on the FMP 2026-03-31 balance sheet.
- Warning Signal: Watch refinancing activity, debt costs, and whether Goodwill And Intangible Assets $8644B remain supported by operating performance.
Capital Efficiency Check
Is AbbVie reinvesting capital efficiently?
AbbVie looks Mixed, because large R&D and acquisition spending can support future growth, but internal cash appears sufficient only if those programs convert into durable commercial returns. The current capital mix raises the bar for reinvestment quality.
Return measures should be judged with leverage, asset intensity, capital expenditure, working capital, and any outside funding needs. A business can post decent returns and still look less efficient if it needs heavy acquisition spending, carries debt, or ties up cash in inventory and intangible assets.
| Capital Measure | Latest Evidence | Quality Test | Investor Meaning |
|---|---|---|---|
| ROIC | Unavailable in the supplied data. | Higher value creation would depend on whether operating margins and capital efficiency stay strong after large R&D and acquisition outlays. | Shows whether invested capital is likely creating operating value, but no direct return figure can be confirmed here. |
| ROE and ROA | Unavailable in the supplied data. | ROE can be lifted by leverage, while ROA usually falls when asset intensity rises; neither should be treated as strong on its own. | Signals shareholder return quality and asset efficiency, but the leverage effect must be separated from real operating strength. |
| Maintenance and Growth Investment | Adjusted R&D Investment of $1380B for 2025, supporting approximately 90 clinical and device programs; ImmunoGen acquisition for approximately $1010B; Cerevel Therapeutics acquisition for approximately $870B in equity value; $450B intangible asset impairment charge related to emraclidine. | The spending clearly supports growth and future option value, but the impairment shows that not every acquired pipeline asset turns into lasting value. | Indicates a high level of capital needed to sustain and expand the pipeline, which raises the performance standard for future returns. |
| Internal Funding Capacity | Operating cash flow, free cash flow, debt capacity, refinancing, dividend funding, and working capital details were not supplied. | Internal funding cannot be confirmed from the provided data, so the investment profile should be treated as only partly evidenced. | Without verified cash and debt data, it is unclear how much growth is funded internally versus through external capital. |
Are AbbVie’s returns on capital sustainable?
The strongest durability source is AbbVie’s broad pipeline and device optionality from heavy R&D and acquisitions, but the $450B emraclidine impairment shows returns can weaken if acquired assets do not convert into commercial value.
- Operating Source: Broad pipeline support from approximately 90 clinical and device programs funded by large R&D investment.
- Funding Requirement: The biggest verified capital need is acquisition and development spending, including ImmunoGen and Cerevel Therapeutics.
- Durability Test: Sustained returns would weaken if future impairment charges, weak margins, or low conversion from pipeline to sales reduce the payoff from invested capital.
If you’re using this topic for a paper or case study, a structured Mission Statement, Vision, & Core Values (2026) of AbbVie Inc. (ABBV), SWOT Analysis, PESTLE Analysis, or Business Model Canvas can help you organize the research into clear arguments.
Financial resilience
What could weaken AbbVie’s financial health?
AbbVie’s resilience looks Mixed. The main buffer is the shift to Skyrizi and Rinvoq, which is helping replace Humira, but the most important verified warning sign is continued Humira erosion, including $454B full-year 2025 Global Humira Net Revenues and $688M in Q1 2026.
AbbVie still has strong cash-generating medicines and a broad pipeline, but resilience depends on how fast newer brands offset older-product decline. The company also has to fund R&D and integration risks while protecting margins and liquidity. For a broader ownership angle, see Exploring AbbVie Inc. (ABBV) Investor Profile: Who's Buying and Why?.
| Pressure | Financial Effect | Existing Protection | Warning Signal |
|---|---|---|---|
| Revenue or Margin Pressure | Humira erosion weakens operating leverage, can slow earnings growth, and can reduce cash available for debt capacity and investment. | Skyrizi and Rinvoq are the main offset, with Q1 2026 Skyrizi Net Revenues of $448B and Rinvoq Net Revenues of $212B. | Watch for weaker combined Skyrizi and Rinvoq sales or continued Humira decline beyond the current pace. |
| Working-Capital or Investment Pressure | Pipeline spending and acquisition-related write-downs can absorb cash and make free cash flow less flexible. | AbbVie has about 90 clinical and device programs, which gives it internal growth options. | Watch adjusted EPS guidance and future impairment disclosures for signs that investment is not converting into earnings. |
| Interest or Refinancing Pressure | Higher debt service or refinancing costs would leave less room for buybacks, R&D, and launches if cash flow weakens. | Product diversification and cash generation help support financing flexibility. | Watch debt, interest, and liquidity trends if operating cash flow slows. |
What financial warning signs should investors monitor at AbbVie?
The top signals are combined Skyrizi and Rinvoq sales, Humira decline, and impairment disclosures. Current Humira erosion is confirmed deterioration; payer and pricing pressure is a future risk unless margin and revenue growth stay stable across the portfolio.
Humira erosion still drives the near-term gap
Humira remains the clearest pressure point after full-year 2025 Global Humira Net Revenues of $454B and Q1 2026 Global Humira Net Revenues of $688M. Skyrizi and Rinvoq are the offset, so combined sales are the next metric to watch.
Acquisition and pipeline write-down risk
AbbVie recorded a $450B emraclidine impairment, which shows that pipeline execution can hurt earnings and cash flow. The mitigation is a broader development base, so adjusted EPS guidance and future impairment disclosures matter most.
Payer and pricing pressure could squeeze margins
Humira formulary displacement and the voluntary three-year US government agreement for lower Medicaid pricing and direct-to-patient cash options show pricing pressure risk. The key check is whether portfolio revenue growth and margins stay resilient.
Financial Scorecard
What does AbbVie’s financial health mean for investors?
AbbVie’s scorecard is overall Strong. The best factor is revenue scale and profitability; the weakest is capital efficiency. The most important condition for the investment case is whether new-product growth can keep offsetting Humira erosion while cash flow stays durable.
| Financial Factor | Rating | Evidence and Investor Meaning |
|---|---|---|
| Revenue and Earnings Quality | Strong | $6116B full-year 2025 net revenues and Q1 2026 net revenues of $1500B show scale; Skyrizi and Rinvoq growth is offsetting Humira erosion, which supports earnings durability. |
| Profitability and Cash | Strong | Q1 2026 GAAP Operating Margin of 7191% points to meaningful operating leverage. Cash generation looks solid, but investors should watch whether cash flow keeps expanding. |
| Balance Sheet and Liquidity | Strong | $982B cash and cash equivalents plus access to refinancing through the $800B senior notes filing suggest good near-term liquidity, even with debt-service needs. |
| Capital Efficiency | Mixed | Heavy R&D, acquisitions, and the $450B impairment make returns harder to judge, so reinvestment quality matters more than headline growth. |
| Financial Resilience | Mixed | AbbVie has strong buffers, but Humira erosion and payer pressure remain real pressure points. For background, see AbbVie Inc. (ABBV): History, Ownership, Mission, How It Works & Makes Money. |
- What Supports the Thesis: Strong revenue scale, high reported profitability, and liquid cash support the case that new products can fund the transition.
- What Challenges the Thesis: Debt, refinancing, and pipeline return risk could pressure flexibility if growth slows or margins weaken.
- What to Monitor: Skyrizi and Rinvoq sales, cash and equivalents, and adjusted EPS guidance.
Those three inputs should drive forecasts, scenario analysis, and valuation work because they link AbbVie’s growth path, balance-sheet strain, and earnings power.
FAQ
What Do Investors Ask About 's Financial Health?
Investors most often ask about the company's revenue quality, profitability, cash generation, debt, liquidity, capital efficiency, and ability to withstand financial pressure.
Why is AbbVie adjusted EPS above GAAP EPS?
AbbVie’s adjusted EPS excludes or adjusts for items that can distort GAAP earnings For full-year 2025, Adjusted Diluted EPS was $1000, while GAAP Diluted EPS was $236, with acquired IPR&D and milestones adding a $276 per share impact
How much cash does AbbVie currently report?
AbbVie filed a Form 10-Q reporting Q1 2026 cash and cash equivalents of $982B FMP’s 2026-03-31 balance sheet lists Cash And Cash Equivalents of $939B, so investors should use the defined source consistently when analyzing liquidity
Can AbbVie refinance debt without reducing liquidity?
AbbVie’s $800B senior notes filing signals active refinancing and capital-structure management The company also had Q1 2026 cash and cash equivalents of $982B, but investors should still monitor interest expense, debt service, and future refinancing terms
What does AbbVie dividend imply about funding?
AbbVie’s Board increased the quarterly dividend by 548% from $155 to $173 per share, and the company paid $173 per share on May 15, 2026 That supports confidence in funding capacity, but debt and cash trends still matter
Which financial warning signs matter most?
The main warning signs are Humira biosimilar erosion, the $450B emraclidine impairment, and payer pricing pressure These risks do not erase AbbVie’s financial strength, but they make Skyrizi and Rinvoq sales, cash, and adjusted EPS guidance important monitoring points